{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.00","upperLimit":"19.00","value":"9.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Time to Response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) ≤ 11.5 mg/dL. Participants were censored on the last CSC assessment day if no response was observed. If there was no post-baseline CSC assessment, time to response was censored on study Day 1.\n\nTime to response was analyzed using Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15.","id":"OG000","title":"Denosumab"}],"paramType":"MEDIAN","populationDescription":"Response Analysis Subset","reportingStatus":"POSTED","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"days"}